Sysmex Corporation

National Center for Global Health and Medicine

National Institute of Advanced Industrial Science and Technology

Nagoya University

Public University Corporation Nagoya City University

Nagoya City University

Youichi Takahama

Shinya Nagai

Masashi Mizokami

Hisashi Narimatsu

Yuzuru Ikehara

Atsushi Kuno

Kazuki Nakabayashi

Maki Sogabe

Yasuhito Tanaka

Chikayuki Tsuruno

Takuya Kyoutou

Takashi Kagawa

Masaya Sugiyama

Noriko Kinoshita

Norio Ohmagari

Hideki Matsuzaki

Yoichiro Horii

Kazunari Yamaguchi

Shunsuke Matsubara

Kiyoaki Ito

Shigeru Kusumoto

Disclosed is a method for assisting prediction of exacerbation of respiratory infection, comprising measuring a biomarker in a specimen collected from a subject suffering from a respiratory infection or a subject suspected of having a respiratory infection, wherein the biomarker is at least one selected from the group consisting of IFNλ3, CCL17, CXCL11, IP-10, IL-6 and CXCL9, and a measured value of the biomarker is used as an index to predict exacerbation of the respiratory infection.

Method for assisting prediction of exacerbation of respiratory infection, and device to assist in predicting exacerbation of respiratory infection

Disclosed is a calibrator comprising IgA having a biotin group and a biotin-binding site, the calibrator being used to obtain a concentration of an IgA aggregate in a sample.

Calibrator, complex, and method for measuring IgA aggregate

An object of the present invention is to provide a method for measuring a glycan-marker glycoprotein, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a method for examining liver disease, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Disclosed is a method for measuring at least one glycoprotein selected from alpha-1-acid glycoprotein (AGP) and Mac-2-binding protein (M2BP) contained in a sample collected from a subject, comprising: measuring AGP binding to a first lectin selected from AOL and MAL, when the glycoprotein is AGP; and measuring M2BP binding to a second lectin selected from WFA, BPL, AAL, RCA120, and TJAII, when the glycoprotein is M2BP.

Method for measuring glycoprotein, method for examining liver disease, reagent for quantitative determination of glycoprotein, and glycan-marker glycoprotein as an index for clinical conditions of liver disease

A method for the early detection of disease through the use of reagents bound by IgM antibodies is described. A reagent and method for the detection of anti-Borna disease virus antibodies are also described.

Method for detecting Borna disease virus infection

Growing community of inventors

Hyogo, Japan

Youichi Takahama